Zydus Pharmaceuticals USA Inc. announced on Tuesday the FDA approval of a generic version of global immunomodulatory drug manufacturer Johnson & Johnson's oral drug Lenalidomide, a strong signal of intensified price competition for the hematologic oncology franchise following the upcoming expiration of blockbuster patents.